Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

Completed · Not applicable

Conditions studied: Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C

In brief

The purpose of this study is to provide medication for opioid use disorder (MOUD) with buprenorphine and naloxone, or bup/nx, pre-exposure prophylaxis (PrEP) for HIV prevention, and/or hepatitis C treatment for persons who inject opioids accessing syringe services programs (SSPs), as part of a comprehensive harm reduction program, and assess the acceptability and feasibility of using telemedicine to implement the program. The initial visit will be conducted in person or remotely via telemedicine given COVID-19 protocols at the SSP site in Greensboro, North Carolina (NC); follow-up visits will be conducted via telemedicine.

Key facts

Study ID
NCT05108935
Run by
Duke University
People needed
17
Starts
2022-02-17
Expected to finish
2023-03-30
Last updated by the study team
2023-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.